Cai Jing Wang·2026-01-13 04:20Core Viewpoint - Rongchang Biopharma has signed an exclusive licensing agreement with AbbVie for RC148, granting AbbVie exclusive rights for development, production, and commercialization outside Greater China [1] Group 1: Financial Aspects - Upon the agreement's effectiveness, Rongchang Biopharma will receive an upfront payment of $650 million [1] - The company is eligible for up to $4.95 billion in milestone payments related to development, regulatory, and commercialization [1] - Additionally, the company will receive a tiered royalty on net sales outside Greater China [1] Group 2: Strategic Implications - This licensing deal is expected to accelerate the global development and commercialization of RC148 [1] - The agreement is anticipated to enhance the company's brand value and international influence [1] Group 3: Risks and Uncertainties - There is uncertainty regarding the final payment amounts due to the inherent risks associated with innovative pharmaceuticals [1]